Navigation Links
A New Marker to Spot Aggressive Breast Cancers?
Date:8/4/2010

By Kathleen Doheny
HealthDay Reporter

WEDNESDAY, Aug. 4 (HealthDay News) -- Low cellular levels of a protein known as ferroportin are tied to recurrent, aggressive breast cancers, new research suggests.

Testing levels of this protein, which eliminates iron from cells, may someday help doctors better predict which breast cancers will return and which need more intensive treatment, the researchers say.

"We had a hint that iron might be important in cancer in general, and particularly in breast cancer, but it hadn't been deeply studied," said Dr. Frank Torti, lead author of the new study and director of the Comprehensive Cancer Center at Wake Forest University Baptist Medical Center, Winston-Salem, NC.

Torti and his team report their findings online Aug. 4 in the journal Science Translational Medicine.

They first looked at isolated human breast cancer cells, finding a low level of the protein in breast cancer cells compared to normal breast cells.

Then, in a series of experiments, the team artificially boosted the protein to near normal levels in an aggressive breast cancer cell line. They found that the cancer cells grew much slower in the presence of added ferroportin.

The researchers also examined levels of the protein in human breast cancer tissue and found the lowest ferroportin levels occurring in the most aggressive cancers.

When they looked at gene activity profiles from more than 800 women included in four large study databases from around the world, the researchers found that decreased ferroportin gene expression is linked with a reduction in breast cancer survival. But high expression is linked with a favorable outcome -- namely, a 10-year survival of more than 90 percent.

The research is in early stages, but may eventually help doctors make a more accurate prognosis for breast cancer, using levels of ferroportin along with other markers such as tumor size and lymph node status, Torti said.

''One day, this discovery may lead to the development of a tissue test which can help predict recurrences based on ferroportin levels," he said. But for now, "we want to look at a larger group of women to confirm the results," Torti said.

"The initial studies they have done suggest this may be another way of predicting the behavior of breast cancer in additon to other available tests," added Dr. Len Lichtenfeld, deputy chief medical officer for the American Cancer Society. "However, as he [Torti] says, there is more research to be done." Whether the finding will prove to be clinically useful, he said, remains to be seen.

Another expert agreed. "If the findings bear out, testing for ferroportin might someday spare women from unnecessary treatments," said Susan Kane, professor of tumor cell biology at the City of Hope cancer center in Duarte, Calif.

"There is some thought that we overtreat, because it is difficult to determine [who needs which treatment to prevent recurrences]," Kane noted.

More information

To learn more about breast cancer, visit the American Cancer Society.

SOURCES: Frank M. Torti, M.D., M.P.H., director, Comprehensive Cancer Center, Wake Forest University Baptist Medical Center, Winston-Salem, N.C.; Len Lichtenfeld, M.D., deputy chief medical officer, American Cancer Society, Atlanta,; Susan Kane, Ph.D., professor, division of tumor cell biology, City of Hope, Duarte, Calif.; Science Translational Medicine, Aug. 4, 2010, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Marker of Ewing sarcoma: Potential new drug target?
2. Researchers find biomarkers in saliva for detection of early-stage pancreatic cancer
3. Personalizing cancer: Creating biomarkers from tumor DNA
4. Damaged protein identified as early diagnostic biomarker for Alzheimers disease in healthy adults
5. Reliable biomarkers needed for early detection of liver cancer
6. More Reliable Biomarkers Needed for Early Detection of Liver Cancer
7. Voyant Health, Ltd. Announces the Launch of KingMark™, a Pioneering Calibration Marker that Calculates the Radiological Magnification of the Hip
8. UAB researchers find 4 biomarkers important in colerectal cancer treatment prognosis
9. BATTLE links potential biomarkers to drugs for lung cancer
10. UAB researchers find 4 biomarkers important in colorectal cancer treatment prognosis
11. Increased EGFR levels may be an early marker of breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
A New Marker to Spot Aggressive Breast Cancers?
(Date:3/23/2017)... ... March 23, 2017 , ... The StayWell Company ... NCQA. The accreditation covers StayWell’s asthma, coronary artery disease, congestive heart failure, chronic ... organizations that have excellent programs for the delivery and improvement of disease management ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... families and businesses of the greater Fort Collins area, has unveiled a collaboration ... ongoing community involvement program. Donations to this worthy cause may now be made ...
(Date:3/23/2017)... ... , ... ?This conference will prominently feature 150+ Hospital and Health System Executive Speakers including: , ... , 43rd President of the United States of America: George W. Bush , ... Out of the Ring: Sugar Ray Leonard , JD, Chairperson, McGuireWoods LLP: Amber ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... improve all aspects of people’s health and nutrition, announced its product Leyzene is ... , Natural Subsistence develops nutritional supplements that help people improve all aspects of ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... The American ... 2017 marks the 40th Anniversary of ABQAURP’s dedication to Health Care Quality and Management ... who have contributed not only to the association, but also to the Health Care ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... On Wednesday, March 22, ... at 5,821.64, up 0.48%; the Dow Jones Industrial ... and the S&P 500 closed at 2,348.45, slightly ... out of nine sectors ended the day in ... on the following Medical Instruments & Supplies equities: ...
(Date:3/23/2017)... 2017 Piramal Pharma ... gibt die Ernennung von Stuart E. Needleman ... globalen Pharmazeutikkunden eine einmalige integrierte End-to-End-Serviceplattform an ... für das erfolgreiche Wachstum und die Umsetzung ... Herr Needleman dafür verantwortlich sein, alle globalen ...
(Date:3/23/2017)... 23, 2017 Merrimack Pharmaceuticals, Inc. (NASDAQ: ... patient in a Phase 1 study of MM-310 in ... encapsulates a novel taxane and targets the EphA2 receptor, ... of many major tumor types, including prostate, ovarian, bladder, ... of this study is an important step in evaluating ...
Breaking Medicine Technology: